Table 2.
In‐Hospital Treatments Among Ideal Patients According to Sex and Year
| Characteristic | Overall, N (%) | P Value | Men, % | P for Trends | Women, % | P for Trends | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Men | Women | 2001 | 2006 | 2011 | 2001 | 2006 | 2011 | ||||
| Acute medication | |||||||||||
| Aspirin ≤24 hoursa | 7023 (88.8) | 2765 (85.9) | <0.0001 | 81.1 | 87.7 | 91.8 | <0.0001 | 78.0 | 85.0 | 88.8 | <0.0001 |
| Clopidogrel ≤24 hoursa | 4454 (56.9) | 1679 (52.5) | <0.0001 | 1.4 | 44.3 | 80 | <0.0001 | 0.8 | 36.5 | 75.5 | <0.0001 |
| β‐Blockers ≤24 hoursa | 2371 (56.8) | 770 (52.6) | 0.005 | 47.8 | 62.7 | 56.1 | 0.095 | 46.4 | 54.8 | 53.1 | 0.202 |
| ACE‐inhibitor/ARBa , b | 5073 (65.8) | 1994 (63.8) | 0.044 | 60.8 | 69.6 | 65.2 | 0.214 | 59.2 | 66.7 | 63.6 | 0.332 |
| Statina , b | 6180 (76.5) | 2476 (75.1) | 0.117 | 30.3 | 75.0 | 91.5 | <0.0001 | 27.8 | 72.6 | 90.4 | <0.0001 |
| Reperfusion therapyb | |||||||||||
| With reperfusion | 2289 (57.5) | 646 (44.2) | <0.0001 | 56.3 | 58.0 | 57.6 | 0.702 | 47.3 | 42.2 | 44.4 | 0.758 |
| Primary PCI | 757 (19.0) | 203 (13.9) | <0.0001 | 8.7 | 15.1 | 24.2 | <0.0001 | 8.4 | 8.9 | 17.7 | <0.0001 |
| Fibrinolytic therapy | 1535 (38.6) | 443 (30.3) | <0.0001 | 47.7 | 43.0 | 33.5 | <0.0001 | 38.9 | 33.3 | 26.8 | 0.0002 |
| Procedurec | |||||||||||
| Nonprimary PCI | 1117 (21.8) | 299 (14.3) | <0.0001 | 9.6 | 19.4 | 24.4 | <0.0001 | 5.6 | 10.2 | 17.1 | <0.0001 |
| Cardiac catheterization | 2414 (47.0) | 669 (31.9) | <0.0001 | 34.2 | 41.7 | 51.1 | <0.0001 | 26.2 | 25.0 | 35.5 | <0.0001 |
ACE, angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; PCI, percutaneous coronary intervention.
a
Only among patients without contraindications for the treatment.
b
During hospitalization.
c
Only among patients admitted into a hospital capable of PCI.